<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01537068</url>
  </required_header>
  <id_info>
    <org_study_id>#6457 Pfizer-WS1895577</org_study_id>
    <nct_id>NCT01537068</nct_id>
  </id_info>
  <brief_title>Desvenlafaxine vs. Placebo Treatment of Chronic Depression</brief_title>
  <official_title>Desvenlafaxine (Pristiq) vs. Placebo in the Treatment of Chronic Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are studying a new antidepressant medicine, desvenlafaxine, for the
      treatment of people with chronic depression. Desvenlafaxine (trade name Pristiq) has been
      approved by the FDA for the treatment of major depression.

      The investigators are testing whether this medicine is also effective for adults with a type
      of chronic depression that is less severe than major depression. This condition is also known
      as dysthymic disorder or dysthymia. Chronic depression, lasting two or more years, often
      causes significant suffering and impairment.

      In addition, the investigators are using MRI imaging, which uses magnetic signals to make
      pictures of the brain's structure and also of its functioning. The purpose of MRI imaging in
      this study is to see whether chronic depression is associated with differences in brain
      structure or functioning, and whether such differences change after medication or placebo
      treatment. To test this MRI scans are done at the start of the study and after 12 weeks of
      medication or placebo treatment. Getting MRI imaging will be an option for participants in
      this study but is not required.

      This study involves a 6 to 12 week double-blind period during which half of the participants
      will take the new medication and half will take a placebo (an inactive look-alike pill).
      After the double blind phase, all subjects can be treated for 12 weeks with an FDA-approved
      antidepressant medication.

      Assessments (of depressive symptoms, social functioning, and personality) will be done by
      study staff and by patients before the study starts, at each study visit for the first 12
      weeks, and again after 24 weeks in the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators wish to study acute efficacy for 12 weeks on a double blind basis and
      continued response after open-label treatment at week 24 follow-up. It is important to
      establish the acute (12 week) efficacy of desvenlafaxine in non-major chronic depression.
      Also, given that non-major chronic depression is by definition chronic, it is important to
      demonstrate that benefit persists at follow-up assessment (24 weeks); this is clinically
      important in trying to alleviate the significant psychosocial morbidity associated with this
      disorder.

      The investigators believe this study will have significant value in the treatment of patients
      with non-major chronic depression, and will add significantly to what remains an extremely
      small scientific literature.

      The investigators would also like to study the effects of desvenlafaxine on brain structure
      and function. Learning that a medication reduces symptoms does not teach us how the
      medication achieves this outcome. Participants in this study can have the opportunity to
      participate in MRI scanning that will help to understand the mechanisms by with
      desvenlafaxine is effective. MRI scans are done prior to starting the clinical trial and then
      again after completing the double blind clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression (HDRS24)</measure>
    <time_frame>Baseline</time_frame>
    <description>HDRS-24 total score, standardly used rating scale for depression. Score 0-7 no depression; Score 8-16 mild depression; Score 17-23 moderate depression; Score 24 and up severe depression. Range= 0 to 75, higher score=worse depression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression (HDRS24)</measure>
    <time_frame>Week 12</time_frame>
    <description>HDRS-24 total score, standardly used rating scale for depression. Score 0-7 no depression; Score 8-16 mild depression; Score 17-23 moderate depression; Score 24 and up severe depression. Range= 0 to 75, higher score=worse depression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessment of overall improvement: based on HDRS and Clinical Global Improvement Scale Response Rate is defined as 50% improvement of Hamd24 summary scores from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Dysthymic Disorder</condition>
  <condition>Dysthymia</condition>
  <condition>Chronic Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Desvenlafaxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Serotonin-norepinephrine reuptake inhibitors (SNRIs) antidepressant drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desvenlafaxine</intervention_name>
    <description>Desvenlafaxine oral dose ranging from 50 to 100 mg/day</description>
    <arm_group_label>Desvenlafaxine</arm_group_label>
    <other_name>Pristiq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo pills</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Inactive comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female outpatients 20 to 65 years of age, inclusive

          -  Principal DSM-5 diagnosis of unipolar non-major Chronic Depressive Disorder (including
             Major Depression in partial remission, Major Depression, residual, Dysthymic Disorder,
             or Depressive Disorder NOS)

          -  Minimum of 2 years duration of the current episode of depressive disorder.

          -  Score of 12 or higher on the Hamilton Depression Scale (24 items) at baseline

        Exclusion Criteria:

          -  Full remission of depression in past 24 months

          -  Current major depression diagnosis, psychotic illness

          -  Current risk of suicide

          -  Drug or alcohol abuse/dependence in past 6 months

          -  Active medical illness

          -  Prior nonresponse to desvenlafaxine

          -  Medical illness contraindicating use of desvenlafaxine

          -  Current or planned pregnancy during study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Hellerstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute, Columbia University Department of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute/3 Columbus Circle Midtown</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Depression Evaluation Service (DES), New York State Psychiatric Institute, Columbia University Department of Psychiatry</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.depression-nyc.org</url>
    <description>Depression Evaluation Service, NY State Psychiatric Institute website</description>
  </link>
  <link>
    <url>http://sklad.cumc.columbia.edu/psychiatry/clinical_trials/View_Trial.php?ID=366&amp;type=simple</url>
    <description>Columbia Psychiatry website, clinical trials</description>
  </link>
  <reference>
    <citation>DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007 May;68(5):677-88.</citation>
    <PMID>17503976</PMID>
  </reference>
  <reference>
    <citation>Levkovitz Y, Tedeschini E, Papakostas GI. Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry. 2011 Apr;72(4):509-14. doi: 10.4088/JCP.09m05949blu.</citation>
    <PMID>21527126</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2012</study_first_submitted>
  <study_first_submitted_qc>February 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2012</study_first_posted>
  <results_first_submitted>June 12, 2017</results_first_submitted>
  <results_first_submitted_qc>September 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 11, 2017</results_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dysthymic disorder</keyword>
  <keyword>Dysthymia</keyword>
  <keyword>Chronic non-major depression</keyword>
  <keyword>Non-major chronic depression</keyword>
  <keyword>Chronic depressive disorder</keyword>
  <keyword>Antidepressant treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Dysthymic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Desvenlafaxine</title>
          <description>Serotonin–norepinephrine reuptake inhibitors (SNRIs) antidepressant drug
Desvenlafaxine: Desvenlafaxine oral dose ranging from 50 to 100 mg/day</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo treatment
Placebo: Matching placebo pills</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>59 met inclusion criteria and started with study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Desvenlafaxine</title>
          <description>SNRI antidepressant drug
Desvenlafaxine: Desvenlafaxine oral dose ranging from 50 to 100 mg/day</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo treatment
Placebo: Matching placebo pills</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.80" spread="14.18"/>
                    <measurement group_id="B2" value="36.28" spread="11.65"/>
                    <measurement group_id="B3" value="38.07" spread="13.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Rating Scale for Depression (HDRS24)</title>
        <description>HDRS-24 total score, standardly used rating scale for depression. Score 0-7 no depression; Score 8-16 mild depression; Score 17-23 moderate depression; Score 24 and up severe depression. Range= 0 to 75, higher score=worse depression</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Desvenlafaxine</title>
            <description>SNRI antidepressant drug
Desvenlafaxine: Desvenlafaxine oral dose ranging from 50 to 100 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treatment
Placebo: Matching placebo pills</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Rating Scale for Depression (HDRS24)</title>
          <description>HDRS-24 total score, standardly used rating scale for depression. Score 0-7 no depression; Score 8-16 mild depression; Score 17-23 moderate depression; Score 24 and up severe depression. Range= 0 to 75, higher score=worse depression</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.63" spread="3.39"/>
                    <measurement group_id="O2" value="14.21" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated Measures of ANOVA</method_desc>
            <param_type>Test of Within-subjects effects</param_type>
            <param_value>2.95</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Rating Scale for Depression (HDRS24)</title>
        <description>HDRS-24 total score, standardly used rating scale for depression. Score 0-7 no depression; Score 8-16 mild depression; Score 17-23 moderate depression; Score 24 and up severe depression. Range= 0 to 75, higher score=worse depression</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Desvenlafaxine</title>
            <description>SNRI antidepressant drug
Desvenlafaxine: Desvenlafaxine oral dose ranging from 50 to 100 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treatment
Placebo: Matching placebo pills</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Rating Scale for Depression (HDRS24)</title>
          <description>HDRS-24 total score, standardly used rating scale for depression. Score 0-7 no depression; Score 8-16 mild depression; Score 17-23 moderate depression; Score 24 and up severe depression. Range= 0 to 75, higher score=worse depression</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.53" spread="3.98"/>
                    <measurement group_id="O2" value="8.24" spread="4.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate</title>
        <description>Assessment of overall improvement: based on HDRS and Clinical Global Improvement Scale Response Rate is defined as 50% improvement of Hamd24 summary scores from baseline.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Desvenlafaxine</title>
            <description>SNRI antidepressant drug
Desvenlafaxine: Desvenlafaxine oral dose ranging from 50 to 100 mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treatment
Placebo: Matching placebo pills</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Assessment of overall improvement: based on HDRS and Clinical Global Improvement Scale Response Rate is defined as 50% improvement of Hamd24 summary scores from baseline.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>Chi-squared</method>
            <param_type>Chi-squared</param_type>
            <param_value>6.32</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Desvenlafaxine</title>
          <description>SNRI antidepressant drug
Desvenlafaxine: Desvenlafaxine oral dose ranging from 50 to 100 mg/day</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo treatment
Placebo: Matching placebo pills</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Patient was treated with placebo and this was an pre-existing condition.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased sleep</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Daytime Sleepiness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Hellerstein MD</name_or_title>
      <organization>NYSPI</organization>
      <phone>646-774-8000</phone>
      <email>desdesk@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

